Advances in adeno-associated virus (AAV)-based gene therapy have demonstrated safety and efficacy in treating various IRDs, as highlighted by the FDA approval of voretigene neparvovec-rzyl (Luxturna) for RPE65-associated retinal dystrophy [20]. This evidence concerns the gene RPE65 and inherited retinal dystrophy.